With new study results presented at this week’s virtual American Diabetes Association (ADA) meeting followed by approval from US regulators to expand the indication for its t:slim X2 insulin pump with Control-IQ technology system, Tandem Diabetes Care Inc. is hoping for brighter days ahead.
The San Diego,CA-based insulin pump maker announced on 17 June that the US Food and Drug Administration has approved an expanded indication for its t:slim X2 insulin pump with Control-IQ technology to children ages six and older
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?